Please assess the completion status of the following clinical trial:

Trial Title: A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 2 diabetes meeting all of the following:~* Minimum 6 month history of diabetes prior to screening visit;~* Fasting C-peptide ≥ 0.8 ng/mL at screening visit;~* HbA1C at screening visit 7-10%;~* Fasting glucose from 140-270 mg/dL on Day -7 following washout of all glucose regulating drugs and supplements.~* BMI at screening visit from 25-35 kg/m2;~* LDL-C at screening ≥ 100 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ETC-1002 (Type: EXPERIMENTAL): ETC-1002 daily Weeks 1-2, 80 mg/day; Weeks 3-4, 120 mg/day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo daily 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).